Abstract
Background
The optimal analgesic strategy for surgical pain after lobectomy remains undefined. To compare the combination of flurbiprofen axetil and dezocine with flurbiprofen axetil alone and dezocine alone, in post-lobectomy patients.
Methods
A single-center, parallel-design double-blind superiority trial, with 5 groups (1:1:1:1:1 ratio) with different combinations of flurbiprofen and dezocine. Patients scheduled for lobectomy will be recruited. The primary outcome is total sufentanil use in patient-controlled intravenous analgesia within the first 24 postoperative hours. Secondary outcomes include pain numeric rating scales at 6th, 12th, 24th, 48th, and 72th postoperative hours, and on the 1st, 3rd, and 6th postoperative months at rest and during coughing, adverse effects from experimental drug treatment, sufentanil use at other time points, analgesia cost, time to chest tube removal, length of hospital stay, time to pass first flatus, and serum level of cytokines. Doctors, patients, and nurses are blinded, and only the manager is unblinded. Analysis is intention-to-treat. Statistical analysis is pre-specified. Statistical comparison of the treatment groups includes one-way analysis of variance followed by Tukey’s post hoc test.
Discussion
Trial did not begin to recruit. Participant recruitment start date is planned to be June 1, 2020. Approximate recruitment end date is May 31, 2021. If successful, the trial may shed light on the use of certain analgesic combinations in post-lobectomy pain control.
Trial registration
Chinese Clinical Trial Registry ChiCTR1800018563. Registered on September 25, 2018.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 West China Hospital, Sichuan University, Department of Thoracic Surgery, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022); Sichuan University, West China School of Medicine, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)
2 West China Hospital, Sichuan University, Department of Thoracic Surgery, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
3 Thomas Jefferson University, Sidney Kimmel School of Medicine, Philadelphia, USA (GRID:grid.265008.9) (ISNI:0000 0001 2166 5843)
4 Sichuan University, West China School of Medicine, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)
5 West China Hospital, Sichuan University, Department of Thoracic Surgery, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022); Thomas Jefferson University, Sidney Kimmel School of Medicine, Philadelphia, USA (GRID:grid.265008.9) (ISNI:0000 0001 2166 5843)
6 West China Hospital, Sichuan University, Department of Anesthesiology, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
7 West China Hospital, Sichuan University, Department of Thoracic Surgery, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022); Sichuan University, West China School of Medicine, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Sichuan University, Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)